HIMS CLASS ACTION: Hims & Hers Health, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by August 25 Legal Deadline (NYSE:HIMS)

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, particularly related to misrepresentation of a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. Group 3: Allegations Against Hims & Hers - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and that its sales complied with FDA regulations [4]. - Novo Nordisk terminated the partnership on June 23, 2025, citing Hims & Hers' deceptive practices and failure to adhere to legal standards regarding compounded drugs [5]. Group 4: Stock Impact - Following the announcement of the partnership termination, Hims & Hers' stock price dropped by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].